Panitumumab

Panitumumab Basic information
Product Name:Panitumumab
Synonyms:Panitumumab;Abx-egf;Abx-egf mab;Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal abx-egf heavy chain), disulfide with human monoclonal abx-egf light chain, dimer;Unii-6A901E312a;Vectibix;Abenix;Panitumumab USP/EP/BP
CAS:339177-26-3
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Panitumumab Structure
Panitumumab Chemical Properties
storage temp. Store at -20°C
Safety Information
MSDS Information
Panitumumab Usage And Synthesis
DescriptionPanitumumab is a recombinant, fully human IgG2 kappa monoclonal antibody that is highly selective for the epidermal growth factor receptor (EGFR), and it is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. Panitumumab blocks the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor (TGF-a) to various EGFR-expressing cell lines, which results in inhibition of EGF-dependent tumor cell activation, induction of apoptosis, and decreased pro-inflammatory cytokine and vascular growth factor production. In vitro, panitumumab binds EGFR with high affinity (KD ? 50pM; IC50 ? 3 nM) in human cervical epidermal cell line A-431. .
OriginatorAbgenix (US)
UsesAntineoplastic.
Brand nameVectibix
Clinical UseMonoclonal antibody:
Treatment of metastatic colorectal cancer
Drug interactionsPotentially hazardous interactions with other drugs
Cytotoxics: avoid with bevacizumab, fluorouracil, irinotecan and oxaliplatin.
Folinic acid: avoid concomitant use.
Live vaccines: avoid concomitant use.


MetabolismSaturable elimination mediated via reticuloendothelial system, and internalisation and degradation of EGFR.
Panitumumab Preparation Products And Raw materials
Ritonavir Sofosbuvir Rapamycin Afatinib (BIBW 2992) Capecitabine Bevacizumab Epothilone D Zoledronic acid Rituximab Trastuzumab Trifluridine CETUXIMAB Icotinib Vinorelbine tartrate Pazopanib 1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol Sorafenib Tacrolimus

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.